ClinicalTrials.gg
CompletedNCT02388724Updated Jun 3, 2019Results posted

Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis

A Phase 3 interventional study of Vonoprazan and Lansoprazole in Erosive Esophagitis, sponsored by Takeda. Completed at 64 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-03.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
481
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing vonoprazan in Esophagitis — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Esophagitis.

Enrollment
4th of 10
481 · median 357
Started
2015
with 1 other
Phase 3
7 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
7 of 10
Takeda

Among the 10 studies testing vonoprazan in Esophagitis, this one is the 4th largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 5th registered.

Esophagitis

123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.

Browse Esophagitis studies →

Open to participants now

1 of the 10 studies testing vonoprazan in Esophagitis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vonoprazan in Esophagitis, or all of them as a file.
02

Study summary

The purpose of the study is to demonstrate the efficacy of vonoprazan (TAK-438) versus lansoprazole in the treatment of erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.

Read the detailed description

The drug being tested in this study is called vonoprazan. Vonoprazan is being tested to treat people who have erosive esophagitis. This study will look at mucosal healing of people who take vonoprazan versus lansoprazole.

This study will enroll approximately 480 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Vonoprazan 20 mg
  • Lansoprazole 30 mg

All participants will be asked to take one tablet and one capsule at the same time each day throughout the study. All participants will be asked to record daytime and nighttime (during sleep) subjective symptoms in a diary on a daily basis.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 11 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone 7-14 days after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Erosive Esophagitis

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has been confirmed in an endoscopy to have erosive esophagitis, ie, the Los Angeles (LA) classification grades A to D within 7 days of the start of the Day 1 (Visit 2).

    Note: The recruitment goal is to ensure that those with LA classification grade C/D will account for more than 30% of all participants enrolled (144/480), with no further recruitment of those with grade A/B considered when they account for more than 70% (336/480) of all participants.

  4. Is aged 18 years old or older (or the local age of consent if that is older), male or female, at the time of signing an informed consent, and is being treated on an outpatient basis for erosive esophagitis, including those admitted temporarily for examination.
  5. A female participant of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 84 days prior to the start of the Observation phase.
  2. Has received TAK-438 in a previous clinical study or as a therapeutic agent.
  3. Is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  4. Has, in the judgment of the investigator, abnormal hematological parameters of , hematocrit, or erythrocytes at Screening.
  5. Has a history or clinical manifestations of serious central nerve system (CNS), cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, endocrine or hematological disease.
  6. Has a history of or allergies to TAK-438 (including its *) or to proton pump inhibitors (PPIs).

    *D-mannitol, crystalline cellulose, hydroxypropyl cellulose, fumaric acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 6000, titanium oxide, yellow iron sesquioxide and iron sesquioxide.

  7. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Observation Phase (Visit 1).
  8. Is required to take excluded medications.
  9. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  10. Has participated in another clinical study within the past 30 days from Visit 1.
  11. Has co-morbidities that could affect the esophagus (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal strictures), a history of radiotherapy or cryotherapy for the esophagus; those with corrosive or physiochemical injury (with the possible inclusion in the study of those with Schatzki's ring or Barrett's esophagus).
  12. Has a history of surgical procedures that may affect the esophagus (eg, fundoplication and mechanical dilatation for esophageal strictures excluding Schatzki's ring) or a history of gastric or duodenal surgery excluding endoscopic removal of benign polyps.
  13. Developed acute upper gastrointestinal bleeding, gastric ulcer (a mucosal defect with white coating) or duodenal ulcer (a mucosal defect with white coating), within 30 days before the start of the Observation Phase (Visit 1) (with the possible inclusion of those with gastric or duodenal erosion).
  14. Has Zollinger-Ellison syndrome or gastric acid hypersecretion or a history of gastric acid hypersecretion.
  15. Is scheduled for surgery that requires hospitalization or requires surgical treatment during his/her participation in the study.
  16. Has a history of or was treated for malignancy within 5 years before the start of the Observation Phase (Visit 1) (the participant may be included in the study if he/she has cured cutaneous basal cell carcinoma or cervical carcinoma in situ).
  17. Has acquired immunodeficiency syndrome (AIDS) or hepatitis, including hepatitis virus carriers: surface antigen (HBsAg) positive, or virus (HCV)-antibody-positive (the participant may be included in the study if he/she is HCV-antigen or HCV-ribonucleic acid [RNA]-negative).
  18. Laboratory tests performed at the start of the Early Observation Phase (visit 1) revealed any of the following abnormalities in the participant:

    1. Creatinine levels: >2 mg/dL (>177 μmol/L).
    2. (ALT) or aspartate aminotransferase (AST), or total levels: > (ULN).
  19. Is active in the Screening Period after the closure of enrollment identified by the Sponsor or the number of participants randomized with LA classification A/B or C/D have reached the required sample size.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
481 participants (actual)

Study arms

  • Experimental
    Vonoprazan 20 mg

    Vonoprazan 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks.

    Drug: Vonoprazan · Drug: Lansoprazole Placebo

  • Active comparator
    Lansoprazole 30 mg

    Lansoprazole 30 mg, capsule, orally, once daily and vonoprazan placebo-matching tablet, orally, once daily for up to 8 weeks.

    Drug: Lansoprazole · Drug: Vonoprazan Placebo

Interventions

  • Vonoprazan tablets

    Also known as: TAK-438

  • Lansoprazole capsules

    Also known as: Prevacid

  • DrugVonoprazan Placebo

    Vonoprazan placebo-matching tablets

  • DrugLansoprazole Placebo

    Lansoprazole placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Endoscopic Healing of Erosive Esophagitis During the 8-Week Treatment Phase

    Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification grade O during the treatment phase. Grade O indicates there are no mucosal breaks in the mucosa.

    Time frame: 8 weeks

Secondary outcomes

  1. Percentage of Participants With Endoscopic Healing of Erosive Esophagitis After 2 Weeks and 4 Weeks of Treatment

    Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification grade O during the treatment phase. Grade O indicates there are no mucosal breaks in the mucosa.

    Time frame: Week 2 and Week 4

  2. Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.

    Time frame: On or after the start of study drug (Day 1) to 14 days after the last dose of study medication (up to 10 weeks)

  3. Number of Participants With Markedly Abnormal Clinical Laboratory Findings

    Clinical Laboratory Safety tests included Chemistry, Hematology and Urinalysis. Number of participants with any markedly abnormal values in laboratory tests collected throughout study is reported. ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, CPK = creatine phosphokinase, BUN = blood urea nitrogen, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit, g/L = grams per liter, U/L = units per liter, mmol/L = millimoles per liter, pmol/L = picomoles per liter.

    Time frame: From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)

  4. Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Findings

    Number of participants with any markedly abnormal 12-lead ECG findings is reported. bpm = beats per minute, msec = milliseconds, CHG= change from baseline.

    Time frame: From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)

  5. Number of Participants With Markedly Abnormal Vital Sign Measurements

    Number of participants with any markedly abnormal vital signs measurements is reported. Vital signs included body temperature (oral, tympanic, or infra-axillary measurement), sitting blood pressure (5 minutes), and pulse. °C = degrees Celsius, mmHg = millimeters of mercury, bpm = beats per minute.

    Time frame: From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)

  6. Change From Baseline in Serum Gastrin

    The change between the serum gastrin values collected at Weeks 2, 4, and 8 relative to baseline.

    Time frame: Baseline and Weeks 2, 4, and 8

  7. Change From Baseline in Serum Pepsinogen I

    The change between the serum pepsinogen I values collected at Weeks 2, 4, and 8 relative to baseline.

    Time frame: Baseline and Weeks 2, 4, and 8

  8. Change From Baseline in Serum Pepsinogen II

    The change between the serum pepsinogen II values collected at Weeks 2, 4, and 8 relative to baseline.

    Time frame: Baseline and Weeks 2, 4, and 8

07

Results

Posted Jun 3, 2019

Participant flow

Participants took part in the study at 56 investigative sites in China, Korea, Taiwan, and Malaysia from 24 March 2015 to 27 July 2017.

Participant flow — Overall Study
MilestoneVonoprazan 20 mgLansoprazole 30 mg
Started244237
Safety set: randomized but not treated02
Completed232224
Not completed1213
Withdrew: Reason not specified01
Withdrew: Major protocol deviation33
Withdrew: Pretreatment event/adverse event32
Withdrew: Voluntary withdrawal65
Withdrew: Randomized but not treated02

Outcome measures

PrimaryPercentage of Participants With Endoscopic Healing of Erosive Esophagitis During the 8-Week Treatment Phase

Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification grade O during the treatment phase. Grade O indicates there are no mucosal breaks in the mucosa.

Time frame:
8 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Healing of Erosive Esophagitis During the 8-Week Treatment Phase
percentage of participantsVonoprazan 20 mgLansoprazole 30 mg
Percentage of Participants With Endoscopic Healing of Erosive Esophagitis During the 8-Week Treatment Phase92.4 (88.310 to 95.456)91.3 (86.890 to 94.607)
Statistical analysis
  • Vonoprazan 20 mg vs Lansoprazole 30 mg · Difference in percentages: 1.1 · 95% CI -3.822 to 6.087
SecondaryPercentage of Participants With Endoscopic Healing of Erosive Esophagitis After 2 Weeks and 4 Weeks of Treatment

Endoscopic healing is defined as participants endoscopically diagnosed as Los Angeles classification grade O during the treatment phase. Grade O indicates there are no mucosal breaks in the mucosa.

Time frame:
Week 2 and Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Healing of Erosive Esophagitis After 2 Weeks and 4 Weeks of Treatment
percentage of participantsVonoprazan 20 mgLansoprazole 30 mg
2 Weeks75.0 (68.970 to 80.391)67.8 (61.341 to 73.869)
4 Weeks85.3 (80.146 to 89.538)83.5 (78.035 to 88.035)
Statistical analysis
  • Vonoprazan 20 mg vs Lansoprazole 30 mg · Difference in percentages: 7.2 · 95% CI -1.054 to 15.371
  • Vonoprazan 20 mg vs Lansoprazole 30 mg · Difference in percentages: 1.8 · 95% CI -4.763 to 8.395
SecondaryNumber of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.

Time frame:
On or after the start of study drug (Day 1) to 14 days after the last dose of study medication (up to 10 weeks)
Reported as:
Count of participants · Participants
Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)
ParticipantsVonoprazan 20 mgLansoprazole 30 mg
Number of Participants Reporting Who Had One or More Treatment-emergent Adverse Event (TEAE)9386
SecondaryNumber of Participants With Markedly Abnormal Clinical Laboratory Findings

Clinical Laboratory Safety tests included Chemistry, Hematology and Urinalysis. Number of participants with any markedly abnormal values in laboratory tests collected throughout study is reported. ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, CPK = creatine phosphokinase, BUN = blood urea nitrogen, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit, g/L = grams per liter, U/L = units per liter, mmol/L = millimoles per liter, pmol/L = picomoles per liter.

Time frame:
From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Clinical Laboratory Findings
ParticipantsVonoprazan 20 mgLansoprazole 30 mg
Hemoglobin (<0.8 x LLN g/L)01
Neutrophils (<0.5 x LLN %)02
Eosinophils (>2 x ULN %)10
Lymphocytes (>1.5 x ULN %)02
ALT (>3 x ULN U/L)02
AST (>3 x ULN U/L)01
GGT (>3 x ULN U/L)43
CPK (>5 x ULN U/L)12
Total Protein (>1.2 x ULN g/L)01
BUN (>10.7 mmol/L)11
Total Cholesterol (>7.72 mmol/L)32
Triglycerides (>2.5 x ULN mmol/L)63
Vitamin B12 (<92 pmol/L)01
SecondaryNumber of Participants With Markedly Abnormal Electrocardiogram (ECG) Findings

Number of participants with any markedly abnormal 12-lead ECG findings is reported. bpm = beats per minute, msec = milliseconds, CHG= change from baseline.

Time frame:
From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Findings
ParticipantsVonoprazan 20 mgLansoprazole 30 mg
Heart Rate (<50 bpm)67
QT Interval (≥460 msec)710
QTcF Interval (≥500, or ≥450 with CHG ≥30 msec)35
SecondaryNumber of Participants With Markedly Abnormal Vital Sign Measurements

Number of participants with any markedly abnormal vital signs measurements is reported. Vital signs included body temperature (oral, tympanic, or infra-axillary measurement), sitting blood pressure (5 minutes), and pulse. °C = degrees Celsius, mmHg = millimeters of mercury, bpm = beats per minute.

Time frame:
From Day 1 to 14 days after the last dose of study medication (up to 10 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Markedly Abnormal Vital Sign Measurements
ParticipantsVonoprazan 20 mgLansoprazole 30 mg
Body Temperature (<35.6 °C)103
Body Temperature (>37.7 °C)20
Systolic Blood Pressure (<85 mmHg)11
Diastolic Blood Pressure (>110 mmHg)10
Pulse (<50 bpm)22
SecondaryChange From Baseline in Serum Gastrin

The change between the serum gastrin values collected at Weeks 2, 4, and 8 relative to baseline.

Time frame:
Baseline and Weeks 2, 4, and 8
Reported as:
Mean · pmol/L
Change From Baseline in Serum Gastrin
pmol/LVonoprazan 20 mgLansoprazole 30 mg
Baseline2.77 ± 4.0843.65 ± 8.622
Change at Week 231.45 ± 28.9958.33 ± 10.190
Change at Week 429.68 ± 29.1896.81 ± 9.969
Change at Week 836.53 ± 37.1084.71 ± 7.727
SecondaryChange From Baseline in Serum Pepsinogen I

The change between the serum pepsinogen I values collected at Weeks 2, 4, and 8 relative to baseline.

Time frame:
Baseline and Weeks 2, 4, and 8
Reported as:
Mean · micrograms per liter (ug/L)
Change From Baseline in Serum Pepsinogen I
micrograms per liter (ug/L)Vonoprazan 20 mgLansoprazole 30 mg
Baseline97.6 ± 53.5499.8 ± 61.99
Change at Week 2456.5 ± 308.22129.3 ± 138.24
Change at Week 4421.8 ± 324.06118.3 ± 113.24
Change at Week 8326.8 ± 233.80117.8 ± 98.03
SecondaryChange From Baseline in Serum Pepsinogen II

The change between the serum pepsinogen II values collected at Weeks 2, 4, and 8 relative to baseline.

Time frame:
Baseline and Weeks 2, 4, and 8
Reported as:
Mean · ug/L
Change From Baseline in Serum Pepsinogen II
ug/LVonoprazan 20 mgLansoprazole 30 mg
Baseline7.5 ± 5.507.8 ± 5.77
Change at Week 244.9 ± 31.318.8 ± 9.63
Change at Week 440.7 ± 26.107.2 ± 5.99
Change at Week 831.0 ± 20.038.0 ± 8.46

Adverse events

Collected over Up to 10 weeks (8 weeks of treatment and 2 weeks of post-treatment follow-up period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vonoprazan 20 mg0/244 (0%)3/244 (1.2%)13/244 (5.3%)
Lansoprazole 30 mg0/235 (0%)3/235 (1.3%)4/235 (1.7%)
Most frequent serious events
Most frequent serious events
EventVonoprazan 20 mgLansoprazole 30 mg
GlaucomaEye disorders0/2441/235
Large intestine polypGastrointestinal disorders0/2441/235
GastroenteritisInfections and infestations0/2441/235
Bile duct stoneHepatobiliary disorders1/2440/235
Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2440/235
Cerebral infarctionNervous system disorders1/2440/235
Most frequent other events
Most frequent other events
EventVonoprazan 20 mgLansoprazole 30 mg
Blood gastrin increasedInvestigations13/2444/235

Baseline characteristics

Randomized set included all randomized participants.

Age, Continuous
Age, Continuous(years)Vonoprazan 20 mgLansoprazole 30 mgTotal
Mean54.1 ± 13.1653.8 ± 12.5353.9 ± 12.84
Sex: Female, Male
Sex: Female, Male(Participants)Vonoprazan 20 mgLansoprazole 30 mgTotal
Female6858126
Male176179355
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vonoprazan 20 mgLansoprazole 30 mgTotal
Asian244237481
Region of Enrollment
Region of Enrollment(Participants)Vonoprazan 20 mgLansoprazole 30 mgTotal
Asia — China143133276
Asia — Malaysia212445
Asia — South Korea5255107
Asia — Taiwan282553
Height
Height(centimeters (cm))Vonoprazan 20 mgLansoprazole 30 mgTotal
Mean166.1 ± 8.24166.3 ± 8.80166.2 ± 8.52
Weight
Weight(kilograms (kg))Vonoprazan 20 mgLansoprazole 30 mgTotal
Mean68.48 ± 12.31170.26 ± 12.13369.35 ± 12.243
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meter (kg/m^2))Vonoprazan 20 mgLansoprazole 30 mgTotal
Mean24.70 ± 3.38925.31 ± 3.43025.00 ± 3.419
Smoking Classification
Smoking Classification(Participants)Vonoprazan 20 mgLansoprazole 30 mgTotal
Never Smoked157137294
Current Smoker4864112
Ex-Smoker393675

11 further baseline measures are reported on the registry.

08

Study locations

64 sites
  • Beijing Chao Yang Hospital
    Beijing, Beijing 100020, China
  • China-Japan Friendship hospital
    Beijing, Beijing 100029, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
  • Beijing Tongren Hospital, Capital Medical Univeristy
    Beijing, Beijing 100370, China
  • PLA.The Military General Hospital of Beijing
    Beijing, Beijing 100700, China
  • Fuzhou General Hospital of Nanjing Military Command
    Fuzhou, Fujian 350100, China
  • Guangdong General Hospital
    Guangzhou, Guangdong 510080, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
  • Union Hospital of Tongji Medical College of Huazhong Science and Techology University
    Wuhan, Hubei 430022, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Techology
    Wuhan, Hubei 430030, China
  • The 2nd Xiangya Hospital Central South University
    Changsha, Hunan 410011, China
  • Chenzhou No.1 People's Hospital
    Chenzhou, Hunan 432000, China
  • The First People's Hospital of Changzhou
    Changzhou City, Jiangsu 213003, China
  • Jiangsu Province People's Hospital
    Nanjing, Jiangsu 210029, China
  • No.2 Hospital Affiliated to Jilin University
    Changchun, Jilin 130041, China
  • Jilin central Hospital
    Jilin, Jilin 132011, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
  • Ruijin Hospital, Shanghai Jiaotong Uni. School of Med.
    Shanghai, Shanghai 200025, China
  • Zhongshan Hospital Fudan University
    Shanghai, Shanghai 200032, China
  • TongJi Hospital of Tongji University
    Shanghai, Shanghai 200065, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • The 2nd Hospital of Tianjin Medical University
    Tianjin, Tianjin 300211, China
  • The First Affiated Hospital of Kunming Medical College
    Kunming, Yunnan 650032, China
  • 2nd Affiliated Hospital, Zhejiang Univ. School of Medicine
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, 100050, China
  • Beijing, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, 0, China
  • 1st Affiliated Hospital of Zhejiang University
    Hangzhou, China
  • The First Affiliated Hospital of NanChang University
    Nanchang, China
  • The Affiliated DrumTower Hospital of Nanjing University
    Nanjing, 210008, China
  • Tianjin, China
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Gyeonggi-do 03080, Korea, Republic of
  • Kyungpook National University Medical Center
    Daegu, Gyeongsangbuk-do 41404, Korea, Republic of
  • Wonkwang University School Of Medicine & Hospital
    Iksan-si, Jeollabuk-do 54538, Korea, Republic of
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • Yeungnam University Hospital
    Daegu, 42415, Korea, Republic of
  • Kyung Hee University Hospital
    Seoul, 02447, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, 03181, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Marys Hospital
    Seoul, 06591, Korea, Republic of
  • Hospital Sultana Bahiyah
    Alor Setar, Kedah 5460, Malaysia
  • Hospital Raja Perempuan Zainab II
    Kota Bahru, Kelantan 15586, Malaysia
  • Hospital Tengku Ampuan Afzan
    Kuantan, Pahang 25100, Malaysia
  • Hospital Queen Elizabeth
    Kota Kinabalu, Sabah 88586, Malaysia
  • Hospital Ampang
    Ampang, Selangor 68000, Malaysia
  • Hospital Universiti Sains Malaysia
    Kelantan, 16150, Malaysia
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, 807, Taiwan
  • E-Da Hospital
    Kaohsiung, 824, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung, 833, Taiwan
  • China Medical University Hospital
    Taichung, 333, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
  • Cheng Ching General Hospital-Chung Kang Branch
    Taichung, 407, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • Taipei Medical University Hospital
    Taipei City, 110, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
  • Tri-Service General Hospital
    Taipei, 114, Taiwan
  • Chang Gung Memorial Hospital, Linkou
    Taoyuan County, 333, Taiwan
09

References and documents

Publications

  • Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, Sheu BS, Chong CF, Funao N, Zhou W, Chen M. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020 Feb;69(2):224-230. doi: 10.1136/gutjnl-2019-318365. Epub 2019 Aug 13. PubMed 31409606 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Jul 2017, 28 months.

Results were first posted in Jun 2019, 1 year 10 months after primary completion.

Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 28 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2015
First posted
Mar 17, 2015
StartActual
Mar 24, 2015
Primary completionActual
Jul 27, 2017
CompletionActual
Jul 27, 2017
Results first posted
Jun 3, 2019
Last update
Jun 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02388724
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 17, 2015
Start date
Mar 24, 2015
Primary completion
Jul 27, 2017
Completion
Jul 27, 2017
Results posted
Jun 3, 2019
Last update
Jun 3, 2019

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion